Amoxicillin/clavulanic acid (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Amoxicillin/clavulanic acid" in English language version.

refsWebsite

Global rank English rank

9web.archive.org

1^st place

6nih.gov

4^th place

5handle.net

102^nd place

76^th place

4doi.org

2^nd place

2clincalc.com

3,912^th place

2,496^th place

2fda.gov

447^th place

338^th place

1tga.gov.au

3,984^th place

2,622^nd place

1hres.ca

low place

1drugs.com

399^th place

333^rd place

1jcdr.net

low place

1espacenet.com

800^th place

676^th place

1pharmaceutical-journal.com

low place

clincalc.com

"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
"Amoxicillin; Clavulanate - Drug Usage Statistics". ClinCalc. Archived from the original on 18 January 2024. Retrieved 14 January 2024.

doi.org

Gillies M, Ranakusuma A, Hoffmann T, Thorning S, McGuire T, Glasziou P, et al. (January 2015). "Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication". CMAJ. 187 (1): E21–E31. doi:10.1503/cmaj.140848. PMC 4284189. PMID 25404399.
Mishra G, Caminero J (2018). "First Successful Use of Low Dose Amoxicillin-Clavulanic Acid in Management of Drug Resistant Tuberculosis". Journal of Clinical and Diagnostic Research. 12 (10): OD08–OD10. doi:10.7860/JCDR/2018/37279.12145. Archived from the original on 7 May 2021. Retrieved 7 May 2021.
Harr T, French LE (December 2010). "Toxic epidermal necrolysis and Stevens-Johnson syndrome". Orphanet Journal of Rare Diseases. 5: 39. doi:10.1186/1750-1172-5-39. PMC 3018455. PMID 21162721.
Davies BE, Boon R, Horton R, Reubi FC, Descoeudres CE (October 1988). "Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin". British Journal of Clinical Pharmacology. 26 (4): 385–390. doi:10.1111/j.1365-2125.1988.tb03395.x. PMC 1386558. PMID 3190988.

drugs.com

"Amoxicillin and Clavulanate Potassium". The American Society of Health-System Pharmacists. Archived from the original on 29 November 2016. Retrieved 8 December 2016.

espacenet.com

worldwide.espacenet.com

GB 2005538, Crowley PJ, "Pharmaceutical compositsions", published 1982-05-26, assigned to Beecham Group Ltd.

fda.gov

accessdata.fda.gov

"Augmentin -- Prescribing Information" (PDF). December 2006. Archived (PDF) from the original on 20 December 2013.

fda.gov

"Recent Animal Drug Approvals". U.S. Food and Drug Administration. 15 March 2024. Archived from the original on 5 April 2024. Retrieved 5 April 2024. This article incorporates text from this source, which is in the public domain.

handle.net

hdl.handle.net

World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 102. hdl:10665/44053. ISBN 9789241547659.
World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
World Health Organization (2019). Critically important antimicrobials for human medicine (6th revision ed.). Geneva: World Health Organization. hdl:10665/312266. ISBN 9789241515528.
World Health Organization (2016). WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. World Health Organization. hdl:10665/250125. ISBN 9789241549639.

hres.ca

hpr-rps.hres.ca

"Regulatory Decision Summary - Amoxicillin Sodium And Potassium Clavulanate For Injection". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.

jcdr.net

Mishra G, Caminero J (2018). "First Successful Use of Low Dose Amoxicillin-Clavulanic Acid in Management of Drug Resistant Tuberculosis". Journal of Clinical and Diagnostic Research. 12 (10): OD08–OD10. doi:10.7860/JCDR/2018/37279.12145. Archived from the original on 7 May 2021. Retrieved 7 May 2021.

nih.gov

ncbi.nlm.nih.gov

Gillies M, Ranakusuma A, Hoffmann T, Thorning S, McGuire T, Glasziou P, et al. (January 2015). "Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication". CMAJ. 187 (1): E21–E31. doi:10.1503/cmaj.140848. PMC 4284189. PMID 25404399.
Harr T, French LE (December 2010). "Toxic epidermal necrolysis and Stevens-Johnson syndrome". Orphanet Journal of Rare Diseases. 5: 39. doi:10.1186/1750-1172-5-39. PMC 3018455. PMID 21162721.
Davies BE, Boon R, Horton R, Reubi FC, Descoeudres CE (October 1988). "Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin". British Journal of Clinical Pharmacology. 26 (4): 385–390. doi:10.1111/j.1365-2125.1988.tb03395.x. PMC 1386558. PMID 3190988.

pubmed.ncbi.nlm.nih.gov

Gillies M, Ranakusuma A, Hoffmann T, Thorning S, McGuire T, Glasziou P, et al. (January 2015). "Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication". CMAJ. 187 (1): E21–E31. doi:10.1503/cmaj.140848. PMC 4284189. PMID 25404399.
Harr T, French LE (December 2010). "Toxic epidermal necrolysis and Stevens-Johnson syndrome". Orphanet Journal of Rare Diseases. 5: 39. doi:10.1186/1750-1172-5-39. PMC 3018455. PMID 21162721.
Davies BE, Boon R, Horton R, Reubi FC, Descoeudres CE (October 1988). "Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin". British Journal of Clinical Pharmacology. 26 (4): 385–390. doi:10.1111/j.1365-2125.1988.tb03395.x. PMC 1386558. PMID 3190988.

pharmaceutical-journal.com

Bryan J (23 June 2011). "Still going strong at 30: co-amoxiclav". The Pharmaceutical Journal. 286: 762. Archived from the original on 22 August 2017. Retrieved 20 December 2020.

tga.gov.au

"Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 6 July 2023. Retrieved 30 March 2024.

web.archive.org

"Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 6 July 2023. Retrieved 30 March 2024.
"Regulatory Decision Summary - Amoxicillin Sodium And Potassium Clavulanate For Injection". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.
"Amoxicillin and Clavulanate Potassium". The American Society of Health-System Pharmacists. Archived from the original on 29 November 2016. Retrieved 8 December 2016.
"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
"Amoxicillin; Clavulanate - Drug Usage Statistics". ClinCalc. Archived from the original on 18 January 2024. Retrieved 14 January 2024.
Mishra G, Caminero J (2018). "First Successful Use of Low Dose Amoxicillin-Clavulanic Acid in Management of Drug Resistant Tuberculosis". Journal of Clinical and Diagnostic Research. 12 (10): OD08–OD10. doi:10.7860/JCDR/2018/37279.12145. Archived from the original on 7 May 2021. Retrieved 7 May 2021.
Bryan J (23 June 2011). "Still going strong at 30: co-amoxiclav". The Pharmaceutical Journal. 286: 762. Archived from the original on 22 August 2017. Retrieved 20 December 2020.
"Augmentin -- Prescribing Information" (PDF). December 2006. Archived (PDF) from the original on 20 December 2013.
"Recent Animal Drug Approvals". U.S. Food and Drug Administration. 15 March 2024. Archived from the original on 5 April 2024. Retrieved 5 April 2024. This article incorporates text from this source, which is in the public domain.